News & Analysis as of

Legislative Agendas State Legislatures Prescription Drugs

White & Case LLP

Arkansas Bans PBMs from Owning Pharmacies, Escalating Scrutiny of Vertical Integration in Pharmacy Distribution

White & Case LLP on

In a first-of-its-kind move, Arkansas Governor Sarah Huckabee Sanders has enacted legislation prohibiting pharmacy benefit managers ("PBMs") from owning or operating pharmacies within the state. The law—Act 624—takes effect...more

McDermott Will & Schulte

Trending in Telehealth: April 2025

Trending in Telehealth highlights monthly state legislative and regulatory developments that impact the healthcare providers, telehealth and digital health companies, pharmacists and technology companies that deliver and...more

McDermott Will & Schulte

California Introduces Bill to Protect 340B Contract Pharmacy Arrangements

California legislators recently introduced AB 1460, which would prohibit prescription drug manufacturers from engaging in discriminatory practices aimed at providers participating in the 340B drug pricing program (covered...more

Sheppard Mullin Richter & Hampton LLP

Oregon Prescription Drug Price Transparency Act in Limbo

On February 16, the U. S. District Court for the District of Oregon struck down the state’s drug price transparency law—The Prescription Drug Price Transparency Act (the “Act”)—ruling that the Act’s annual price increase...more

Sheppard Mullin Richter & Hampton LLP

Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives

Connecticut is the latest state to join the efforts of jurisdictions such as Oregon, Nevada, Washington D.C., and the City of Chicago, Illinois, in further regulating the activities of pharmaceutical representatives. In June,...more

Nelson Mullins Riley & Scarborough LLP

Gold Dome Report – Legislative Day 9 2022

The General Assembly got back to work on Tuesday with a slate full of committee meetings to advance bills and resolutions through the legislative gauntlet. But before legislators receded into the meeting rooms in the State...more

White & Case LLP

States Remain the Drivers of New Drug Pricing Legislation As Washington Weighs In

White & Case LLP on

State legislatures continue to push forward on drug pricing with legislation designed to reduce the cost of prescription drugs. Recent steps across a number of states include laying the groundwork for effective...more

Nelson Mullins Riley & Scarborough LLP

Gold Dome Report — Legislative Day 39

As expected (and feared), March madness has engulfed the State Capitol as legislators press to pass measures on the penultimate day of the 2021 Legislative Session. From late-arriving Rules Committee substitutes and...more

Nelson Mullins Riley & Scarborough LLP

Gold Dome Report — Legislative Day 29

After a late-adjourning Crossover Day, legislators and lobbyists largely slept late today, with one notable exception — those appearing before the Human Development Subcommittee of the Senate Appropriations Committee, which...more

Spilman Thomas & Battle, PLLC

A 2020 Pennsylvania Legislative Update

When the 2019-2020 legislative session began, no one could have predicted what challenges Pennsylvania and the General Assembly would encounter with the outbreak of COVID-19. The rules changed to permit remote voting, and the...more

White & Case LLP

Growing Web of State Drug-Pricing Legislation Increases Challenges for Pharmaceutical Manufacturers and Other Industry...

White & Case LLP on

With proposed federal legislation on pause, state legislatures continue to target the pricing of pharmaceuticals, passing a number of new laws in 2020. As complexity at the state level continues to increase, pharmaceutical...more

Downs Rachlin Martin PLLC

Vermont Health Care Update | Week 18

House committees consider Interstate Nurse Licensure Compact  - The House Health Care and Government Operations Committees held separate hearings on Tuesday on S.125, a bill that allows Vermont to join the Interstate Nurse...more

Skadden, Arps, Slate, Meagher & Flom LLP

Drug Pricing Concerns Drive Continued DOJ Focus on Life Sciences Companies

In 2019, U.S. Department of Justice (DOJ) enforcement activity targeting drug and device manufacturers jumped sharply over the prior year, reflecting an increased focus on fraud and abuse in the life sciences sector. More...more

13 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide